Nasdaq

European Commission Approves Subcutaneous Formulation of Entyvio® (Vedolizumab) for use as Maintenance Therapy in Adults with Moderately to Severely Active Ulcerative Colitis ...

− Approval makes Entyvio the only maintenance therapy approved across Europe with both intravenous and subcutaneous formulation options for adult patients with ulcerative colitis or Crohn’s disease − ...
Agence France-Presse

Positive Phase 3 Data Demonstrate Potential for ENTYVIO® (vedolizumab) to Address Treatment Gap for Children and Adolescents with Moderate to Severe Ulcerative Colitis

Takeda (TSE:4502/NYSE:TAK) today announced positive data from the pivotal Phase 3 KEPLER trial, which demonstrated that ENTYVIO ® (vedolizumab) can offer the possibility of clinical remission for ...
Monthly Prescribing Reference

Entyvio for Subcutaneous Use Approved for Maintenance in Crohn Disease

Credit: Takeda. The approval was based on data from the phase 3 VISIBLE 2 trial. Results showed 48% of patients treated with vedolizumab SC were in clinical remission at week 52 compared with 34% of ...
Business Insider

New Real-World Analyses Support Effectiveness and Safety of Entyvio(R) (vedolizumab) for Ulcerative Colitis and Crohn's Disease

OSAKA, Japan, May 8, 2017 /PRNewswire/ -- Takeda Pharmaceutical Company Limited [TSE: 4502], ("Takeda") today announced the presentation of eight real-world analyses supporting the effectiveness and ...
Healio

Takeda’s Entyvio snags second FDA approval as ‘subcutaneous option’ for Crohn’s disease

Please provide your email address to receive an email when new articles are posted on . The FDA has approved subcutaneous administration of Takeda Pharmaceuticals’ Entyvio for maintenance therapy in ...
Nasdaq

Safety and Efficacy of Subcutaneous Entyvio® (Vedolizumab) Sustained During Long-term Maintenance Therapy in Adults with Moderately to Severely Active Ulcerative Colitis

OSAKA, Japan--(BUSINESS WIRE)-- Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced interim results from the VISIBLE open-label extension (OLE) study on the long-term ...
AOL

Does Medicare Cover Entyvio

Entyvio is a brand-name prescription medication known as a biologic. Its active ingredient is called vedolizumab. Generic versions of biologic medications are called biosimilars. But only the ...
Healio

Model-informed Entyvio dosing increases remission in Crohn's

Please provide your email address to receive an email when new articles are posted on . “Rates of endoscopic remission in patients with CD rarely exceed 30% and it remains unknown whether dosing ...
News Medical

Entyvio Pen

The full CMI on the next page has more details. If you are worried about using this medicine, speak to your doctor or pharmacist. Entyvio pre-filled pen for subcutaneous injection contains the active ...
AOL

Medicare coverage for Entyvio: What to know

Entyvio is a brand-name prescription biologic drug. It contains the active ingredient vedolizumab. Biosimilars are generic versions of biologic medications, but only the brand-name version of this ...
Business Insider

New Real-World Analyses Support Effectiveness and Safety of Entyvio® (vedolizumab) for Ulcerative Colitis and Crohn's Disease

Data showcased at Digestive Disease Week (DDW) 2017 meeting include presentations of new analyses from the VICTORY consortium OSAKA, Japan, May 8, 2017 /PRNewswire/ -- Takeda Pharmaceutical Company ...